keyword
MENU ▼
Read by QxMD icon Read
search

Extrapyramidal Symptoms

keyword
https://www.readbyqxmd.com/read/29325180/sertindole-eeg-analysis-tolerability-and-clinical-efficacy
#1
Adam Kroc, Marta Dębicka, Aleksandra Wierzbicka, Lidia Wołkow, Wojciech Jernajczyk, Adam Wichniak
INTRODUCTION: One of the common side effects of antipsychotic drugs is excessive sedation. The treatment with antipsychotics often manifests as an increase in slow wave activity in electroencephalography (EEG). The aim of this study was to analyze EEG recordings of patients treated with a non-sedative antipsychotic drug sertindole with regard to its adverse effects and clinical efficacy. PATIENTS AND METHODS: EEG recordings of 45 patients (27 females, mean age 30...
January 11, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29318783/tak-063-a-novel-pde10a-inhibitor-with-balanced-activation-of-direct-and-indirect-pathways-provides-a-unique-opportunity-for-the-treatment-of-schizophrenia
#2
REVIEW
Kazunori Suzuki, Haruhide Kimura
The basal ganglia regulates motor, cognitive, and emotional behaviors. Dysfunction of dopamine system in this area is implicated in the pathophysiology of schizophrenia characterized by positive symptoms, negative symptoms, and cognitive deficits. Medium spiny neurons (MSNs) are principal output neurons of striatum in the basal ganglia. Similar to current antipsychotics with dopamine D2 receptor antagonism or partial agonism, phosphodiesterase 10A (PDE10A) inhibitors activate indirect pathway MSNs, leading to the expectation of therapeutic potential for the treatment of psychosis...
January 9, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29278968/clinical-improvement-relapse-and-treatment-adherence-with-paliperidone-palmitate-1-month-formulation-1-year-treatment-in-a-naturalistic-outpatient-setting
#3
Rosaria Di Lorenzo, Michela Cameli, Chiara Piemonte, Marisa Bolondi, Giulia Landi, Gabriella Pollutri, Ludovica Spattini, Valentina Moretti, Paola Ferri
PURPOSE: To evaluate paliperidone palmitate 1-month formulation (PP1M) effectiveness in a naturalistic outpatient psychiatric setting. MATERIALS AND METHODS: We collected data from 50 outpatients affected by schizophrenia disorders treated with PP1M for 12 months in an Italian Mental Health Department. After analyzing selected demographic, clinical and pharmacological variables, we performed mirror analysis to compare psychiatric hospitalizations and urgent consultations required by the same patient 6 and 12 months before and after PP1M implementation (primary outcome)...
December 27, 2017: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/29276595/one-patient-with-schizophrenia-showed-reduced-drug-induced-extrapyramidal-symptoms-as-a-result-of-an-alternative-regimen-of-treatment-with-paliperidone-3-and-6-mg-every-other-day
#4
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Hideo Matsumoto, Katsunaka Mikami
Background: Schizophrenia is a chronic disease that requires long-term management with antipsychotics. Antipsychotic drugs are given by tapering their dose, extending the dosing interval, and so on, as part of a treatment strategy to minimize the adverse effects while at the same time maintaining efficacy. Methods: We report the case of one patient with schizophrenia in whom the clinical symptoms were alleviated after treatment with 6 mg paliperidone. However, the patient developed extrapyramidal syndrome, for which 3 and 6 mg paliperidone were administered alternately every other day...
2017: SAGE Open Medical Case Reports
https://www.readbyqxmd.com/read/29273299/-self-intermittent-catheterization-and-urinary-retentions-in-parkinsonian-syndromes
#5
E Savard, A Declemy, V Coindreau, F Babany, C Chesnel, A Charlanes, F Le Breton, G Amarenco
INTRODUCTION: Lower urinary tract symptoms are common in Parkinson diseases, especially chronic urinary retention. In case of significant and symptomatic postvoid residual, a specific treatment is necessary in order to empty the bladder and nowadays the gold standard of such neurogenic bladder is based on self-intermittent-catheterizations, if possible at all. We carried out a retrospective study about feasibility and outcomes of self-intermittent-catheterizations in this population. METHODS: Retrospective study with qualitative and quantitative, clinical and instrumental (urodynamic) assessment, of lower urinary tract symptoms as urinary retention in extrapyramidal syndromes...
December 19, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/29243130/neuroleptic-malignant-syndrome-as-a-presenting-feature-of-subacute-sclerosing-panencephalitis
#6
Divyani Garg, Varun Reddy, Rajesh Kumar Singh, Deepa Dash, Rohit Bhatia, Manjari Tripathi
Subacute sclerosing panencephalitis (SSPE) is a slowly progressive degenerative disorder caused by measles virus. It is characterised by typical clinical and electrophysiological features in the form of slow myoclonic jerks, with progressive cognitive impairment, visual symptoms, and periodic complexes on EEG, with raised titres of anti-measles antibodies in CSF and serum. Atypical presentations of SSPE have been reported including brainstem involvement, ADEM-like presentation, acute encephalitis, and cerebellar ataxia...
December 14, 2017: Journal of Neurovirology
https://www.readbyqxmd.com/read/29221470/potential-diagnostic-markers-of-olanzapine-efficiency-for-acute-psychosis-a-focus-on-peripheral-biogenic-amines
#7
A E Taraskina, R F Nasyrova, A M Zabotina, D N Sosin, К А Sosina, E E Ershov, M N Grunina, E M Krupitsky
BACKGROUND: Biomarkers are now widely used in many fields of medicine, and the identification of biomarkers that predict antipsychotic efficacy and adverse reactions is a growing area of psychiatric research. Monoamine molecules of the peripheral bloodstream are possible prospective biomarkers based on a growing body of evidence indicating that they may reflect specific changes in neurotransmitters in the brain. The aim of this study was to detect peripheral biogenic amine indicators of patients with acute psychosis and to test the correlations between the biological measures studied and the psychopathological status of the patients...
December 8, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29200857/reversal-of-olanzapine-induced-weight-gain-in-a-patient-with-schizophrenia-by-switching-to-asenapine-a-case-report
#8
Kosuke Okazaki, Kazuhiko Yamamuro, Toshifumi Kishimoto
Aims: Antipsychotics are effective for treating schizophrenia, but atypical antipsychotics can cause several adverse side effects including weight gain, hyperprolactinemia, and extrapyramidal symptoms. Moreover, weight gain increases the risk of metabolic diseases. Methods: We treated a case of olanzapine-induced weight gain in a 41-year-old man with schizophrenia by switching his medication from olanzapine to asenapine. Results: The weight gain improved after switching the medication, from 80...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29193034/hypermanganesemia-with-dystonia-polycythemia-and-cirrhosis-in-10-patients-six-novel-slc30a10-mutations-and-further-phenotype-delineation
#9
M S Zaki, M Y Issa, H M Elbendary, H El-Karaksy, H Hosny, C Ghobrial, A El Safty, A El-Hennawy, A Oraby, L Selim, M S Abdel-Hamid
Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early-onset dystonia, and liver cirrhosis (HMDPC). To-date only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1W images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients...
November 28, 2017: Clinical Genetics
https://www.readbyqxmd.com/read/29189977/efficacy-and-safety-of-atypical-antipsychotics-for-behavioral-symptoms-of-dementia-among-patients-residing-in-long-term-care
#10
A S Sturm, K E Trinkley, K Porter, Milap C Nahata
Background There are limited options for the treatment of behavioral and psychological symptoms of dementia (BPSD). Objective Evaluate the efficacy and safety of using atypical antipsychotics for BPSD among patients residing in long-term care. Setting Long term care community facility in the United States. Methods Retrospective observational study of patients residing in a long-term care facility with a diagnosis of dementia not trauma-induced with documented BPSD treated with an atypical antipsychotic for at least 2 weeks...
November 30, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29185545/movement-disorders-and-chronic-psychosis-five-new-things
#11
Davide Martino, Francesca Morgante
Purpose of review: To discuss selected peer-reviewed research articles published between 2014 and 2016 and highlight 5 clinically relevant messages related to hyperkinetic and hypokinetic movement disorders in patients with chronic psychosis. Recent findings: A recent population-based study complemented data from clinical trials in showing increased risk of developing extrapyramidal symptoms with antipsychotic use. A community service-based longitudinal study showed that dopamine transporter imaging could help identify subgroups of patients with parkinsonism associated with antipsychotics with a progressive course, potentially manageable with l-dopa...
April 2017: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/29183417/neurological-soft-signs-significantly-differentiate-schizophrenia-patients-from-healthy-controls
#12
Konstantinos N Fountoulakis, Panagiotis Panagiotidis, Xenia Gonda, Vasilios Kimiskidis, Ioannis Nimatoudis
OBJECTIVE: Neurological soft signs (NSS) are a group of minor non-localisable neurological abnormalities found more often in patients with schizophrenia. The aim of the current study was to test for the effect of gender, age, parental age, age at onset and clinical symptomatology on NSS. Material and methods The study sample included 133 patients suffering from schizophrenia according to DSM-IV-TR (77 males and 56 females; aged 33.55±11.22 years old) and 122 normal controls (66 males and 56 females; aged 32...
November 29, 2017: Acta Neuropsychiatrica
https://www.readbyqxmd.com/read/29174529/adjunctive-azapirone-for-schizophrenia-a-meta-analysis-of-randomized-double-blind-placebo-controlled-trials
#13
Wei Zheng, Xiao-Hong Li, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Yu-Ping Ning, Yu-Tao Xiang
Azapirones, which are serotonin1A (5-HT1A) receptor partial agonists, have been used as an adjunctive treatment for schizophrenia with mixed results. This is a meta-analysis of the efficacy and tolerability of azapirones for schizophrenia based on randomized, double-blind, placebo-controlled trials (RCTs). English and Chinese databases were systematically and independently searched by two investigators. Data were extracted and analyzed using the RevMan software (version 5.3). Seven RCTs (n = 368) of azapirones (buspirone in 6 RCTs and tandospirone in 1 RCT) were identified and analyzed...
November 21, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29174093/novel-gnb1-de-novo-mutation-in-a-patient-with-neurodevelopmental-disorder-and-cutaneous-mastocytosis-clinical-report-and-literature-review
#14
Krzysztof Szczałuba, Anna Biernacka, Krystyna Szymańska, Piotr Gasperowicz, Joanna Kosińska, Małgorzata Rydzanicz, Rafał Płoski
De novo monoallelic mutations in the GNB1 gene, encoding a β subunit of heterotrimeric G proteins, cause a newly recognized disorder with the typical clinical picture of severe developmental delay/intellectual disability, hypotonia and extrapyramidal symptoms. We describe another case of the condition with manifestations of cutaneous mastocytosis associated with a novel do novo mutation GNB1NM_001282539.1: c.230G > T; p.(Gly77Val). We also present the detailed clinical and etiopathogenetic discussion on previously diagnosed patients as well as suggestions for the link of the mutation with skin disease...
November 22, 2017: European Journal of Medical Genetics
https://www.readbyqxmd.com/read/29171491/-the-efficacy-and-tolerability-of-pericyazine-in-the-treatment-of-patients-with-schizotypal-disorder-organic-personality-disorders-and-pathocharacterological-changes-within-personality-disorders
#15
D S Danilov
AIM: To assess the efficacy and tolerability of pericyazine in the treatment of patients with mental disorders manifesting with psychopathic-like symptoms and correction of pathocharacterological disorders in patients with personality disorders during the short-term admission to the hospital or the long-term outpatient treatment. MATERIAL AND METHODS: Sixty-three patients with schizotypal personality disorder and organic personality disorder with psychopathic-like symptoms and pathocharacterological changes within the diagnosis of dissocial personality disorder and borderline personality disorder were examined...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29170943/asenapine-treatment-in-pediatric-patients-with-bipolar-i-disorder-or-schizophrenia-a-review
#16
REVIEW
Ekaterina Stepanova, Bradley Grant, Robert L Findling
Asenapine, administered as a twice-daily (BID) sublingual tablet, is approved in the US as monotherapy for the acute treatment of manic and mixed episodes of bipolar I disorder in children and adolescents aged 10-17 years based on the positive results of one 3-week, double-blind, placebo-controlled study; the recommended dose is 2.5-10 mg BID. Although asenapine has been studied in pediatric patients with schizophrenia, it is not approved for this indication. Asenapine is not approved for pediatric use in bipolar I disorder or schizophrenia in other major markets...
November 23, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29159549/-diagnostics-of-wilson-s-disease
#17
REVIEW
W Hermann, D Huster
Wilson's disease is a rare genetic but treatable metabolic disorder which has a favorable prognosis when diagnosed early and treated adequately. Therefore, knowledge of this rare clinical condition and a reliable diagnosis are indispensable. The diagnostic work-up is initiated in cases of unexplained acute or chronic liver disease and/or an extrapyramidal motor disturbance occurring mostly between the 5th and 45th years of life. Manifestations with initial symptoms have occasionally been observed at an age younger than 1 year and later than 70 years...
November 20, 2017: Der Nervenarzt
https://www.readbyqxmd.com/read/29128871/neural-substrate-of-unrelenting-negative-symptoms-in-schizophrenia-a-longitudinal-resting-state-fmri-study
#18
Mingli Li, Wei Deng, Tushar Das, Yinfei Li, Liansheng Zhao, Xiaohong Ma, Yingcheng Wang, Hua Yu, Xiaojing Li, Ya-Jing Meng, Qiang Wang, Lena Palaniyappan, Tao Li
Developing a mechanistic insight into the specific brain processes that underpin improvement in negative symptoms can help us design novel chemical and physical treatments against these unrelenting symptoms. The aim of the present study is to explore the longitudinal changes in the brain's regional functional efficiency that accompany improvement in negative symptoms seen in first-episode patients with schizophrenia when treated with antipsychotic for 1 year. Forty-seven first-episode patients with schizophrenia were scanned at a drug-naive baseline state and followed up for 1 year to identify negative symptom responders (Rn) and non-responders (NRn)...
November 11, 2017: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/29122973/capsaicin-cream-for-treatment-of-cannabinoid-hyperemesis-syndrome-in-adolescents-a-case-series
#19
Jessica Graham, Michael Barberio, George Sam Wang
Cannabinoid hyperemesis syndrome (CHS) is an underrecognized diagnosis among adolescents. In the adult literature, it is characterized as nausea, vomiting, and abdominal pain in patients with chronic marijuana use. CHS is often refractory to the standard treatment of nausea and vomiting. Unconventional antiemetics, such as haloperidol, have been successful in alleviating symptoms; however, even 1 dose of haloperidol can lead to grave adverse effects, such as dystonia, extrapyramidal reactions, and neuroleptic malignant syndrome...
December 2017: Pediatrics
https://www.readbyqxmd.com/read/29112001/a-phase-ii-study-to-evaluate-the-pharmacokinetics-safety-and-tolerability-of-risperidone-ism-multiple-intramuscular-injections-once-every-4-weeks-in-patients-with-schizophrenia
#20
Lourdes A Carabias, Jordi Llaudó, Ignacio Ayani, Javier Martínez, Robert E Litman, Ibón Gutierro
This study characterized the pharmacokinetics, safety, and tolerability of Risperidone ISM, a new long-acting intramuscular formulation, for monthly administration without oral supplementation. Patients with schizophrenia received multiple intramuscular injections of 75 mg in the gluteal or deltoid muscle at 28-day intervals. Of the 70 randomized patients, 67 received at least one dose of study medication. The mean Cmax of the active moiety was achieved 24-48 h (tmax) after each administration, regardless of injection site...
November 3, 2017: International Clinical Psychopharmacology
keyword
keyword
7606
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"